Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CXA-101 · 1 trial · 1 indication
Microbiological response is eradication for each baseline pathogen
Microbiological response is eradication for each baseline pathogen
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | CXA-101 |
| 2 | ACTIVE_COMPARATOR | Ceftazidime |
| Name | Type | Description |
|---|---|---|
| CXA-101 | DRUG | intravenous |
| Ceftazidime | DRUG | intravenous |
Inclusion Criteria: 1. Males and females 18 to 90 years of age, inclusive. 2. Pyuria (white blood cell \[WBC\] count \> 10/µL in unspun urine or ≥ 10 per high power field in spun urine) 3. Clinical signs and/or symptoms of cUTI, either of: a. Pyelonephritis, as indicated by both of the followin...
CXA-101 is an investigational small molecule being studied for complicated urinary tract infections, complicated intra-abdominal infections, and in healthy subjects for safety evaluations. It is in Phase 2 clinical development for the infectious disease therapeutic area.
CXA-101 is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in infectious disease indications.
CXA-101 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and effectiveness.
CXA-101 has completed three clinical trials. NCT00921024 studied it in complicated urinary tract infections with 129 participants. NCT01147640 evaluated it in complicated intra-abdominal infections with 122 participants. NCT02508753 assessed its effects on QT/QTc intervals in 52 healthy subjects.
CXA-101 is the base drug, and CXA-101/Tazobactam is a combination formulation that includes tazobactam. Clinical trials have evaluated both the single agent and the combination, with the combination studied in intra-abdominal infections and healthy subjects.